GoodRx Holdings Forecast, price target & analysts
GoodRx Holdings Target price 2025 - Analyst rating & recommendation
GoodRx Holdings Classifications & Recommendation:
GoodRx Holdings Price Target
| Target Price | $6.69 |
| Price | $4.98 |
| Potential |
34.38%
register free of charge
|
| Number of Estimates | 13 |
|
13 Analysts have issued a price target GoodRx Holdings 2026 .
The average GoodRx Holdings target price is $6.69.
This is
34.38%
register free of charge
$10.00
100.80%
register free of charge
$4.25
14.66%
register free of charge
|
|
| A rating was issued by 15 analysts: 10 Analysts recommend GoodRx Holdings to buy, 4 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the GoodRx Holdings stock has an average upside potential 2026 of
34.38%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2029
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 750.27 | 793.57 |
| 2.12% | 5.77% | |
| EBITDA Margin | 21.75% | 32.78% |
| 76.04% | 50.74% | |
| Net Margin | -1.02% | 2.95% |
| 74.46% | 390.61% |
17 Analysts have issued a sales forecast GoodRx Holdings 2024 . The average GoodRx Holdings sales estimate is
This results in the following potential growth metrics:
17 Analysts have issued an GoodRx Holdings EBITDA forecast 2024. The average GoodRx Holdings EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 GoodRx Holdings Analysts have issued a net profit forecast 2024. The average GoodRx Holdings net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2029
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.02 | 0.06 |
| 75.00% | 400.00% | |
| P/E | 79.53 | |
| EV/Sales | 2.50 |
10 Analysts have issued a GoodRx Holdings forecast for earnings per share. The average GoodRx Holdings <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the GoodRx Holdings stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
GoodRx Holdings...
Current GoodRx Holdings Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Citigroup | Locked ➜ Locked | Locked | Jan 10 2025 |
| Keybanc | Locked ➜ Locked | Locked | Jan 08 2025 |
| Morgan Stanley | Locked ➜ Locked | Locked | Dec 17 2024 |
| Citigroup | Locked ➜ Locked | Locked | Nov 13 2024 |
| Barclays | Locked ➜ Locked | Locked | Nov 11 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Citigroup: Locked ➜ Locked
|
Jan 10 2025 |
|
Locked
Keybanc: Locked ➜ Locked
|
Jan 08 2025 |
|
Locked
Morgan Stanley: Locked ➜ Locked
|
Dec 17 2024 |
|
Locked
Citigroup: Locked ➜ Locked
|
Nov 13 2024 |
|
Locked
Barclays: Locked ➜ Locked
|
Nov 11 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
